{"id":2442,"date":"2010-12-13T09:49:45","date_gmt":"2010-12-13T14:49:45","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=2442"},"modified":"2010-12-13T09:49:45","modified_gmt":"2010-12-13T14:49:45","slug":"u-s-biotech-japanese-pharma-partner-on-protein-drugs","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=2442","title":{"rendered":"U.S. Biotech, Japanese Pharma Partner on Protein Drugs"},"content":{"rendered":"<figure id=\"attachment_2444\" aria-describedby=\"caption-attachment-2444\" style=\"width: 250px\" class=\"wp-caption alignright\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/Protein_NASA.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-2444\" title=\"Protein_NASA\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/Protein_NASA.jpg\" alt=\"Protein illustration (NASA)\" width=\"250\" height=\"249\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/Protein_NASA.jpg 250w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/12\/Protein_NASA-150x150.jpg 150w\" sizes=\"auto, (max-width: 250px) 100vw, 250px\" \/><\/a><figcaption id=\"caption-attachment-2444\" class=\"wp-caption-text\">(NASA)<\/figcaption><\/figure>\n<p>Anaphore Inc. of La Jolla, California and <a href=\"http:\/\/www.mt-pharma.co.jp\/e\/\">Mitsubishi Tanabe Pharma Corporation<\/a> in Osaka, Japan formed a partnership for research, development, and commercialization of protein therapies for autoimmune disease. The partnership will focus on disorders such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis.<\/p>\n<p>The companies will make use of Anaphore&#8217;s technology, which generates novel trivalent proteins that can be programmed to bind to, and activate or inhibit nearly any target of interest. The agreement stipulates an initial target for the research program, but Mitsubishi Tanabe&#8217;s research lab in San Diego, California, can nominate two additional autoimmune targets against which Anaphore would develop potential protein therapies.<\/p>\n<p>Mitsubishi Tanabe Pharma will pay $5 million for the first target and contribute research funds. Anaphore will also receive milestone payments totaling $110 million and tiered royalties on sales, provided the nominated molecule achieves full commercialization. Financial terms are substantially similar if two more targets are identified.<\/p>\n<p>After joint identification and early development of the first targets, Mitsubishi Tanabe Pharma will be responsible for their late stage development and commercialization.<\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anaphore Inc. of La Jolla, California and Mitsubishi Tanabe Pharma Corporation in Osaka, Japan formed a partnership for research, development, and commercialization of protein therapies for autoimmune disease. The partnership will focus on disorders such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. The companies will make use of Anaphore&#8217;s technology, which generates novel trivalent [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[21,108,64,27],"class_list":["post-2442","post","type-post","status-publish","format-standard","hentry","category-ventures","tag-biotech","tag-japan","tag-life-sciences","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2442"}],"version-history":[{"count":2,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2442\/revisions"}],"predecessor-version":[{"id":2445,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2442\/revisions\/2445"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}